Corbus Pharmaceuticals Presented Data from Phase 2 Study of Anabasum for the Treatment of Systemic Sclerosis at the EULAR 2017 Annual Meeting

Business Insider—June 15, 2017

In a statement released by Corbus Pharmaceuticals Holdings, Inc., HSS rheumatologist Robert F. Spiera, MD, presented his study on systemic sclerosis at the European League Against Rheumatism Annual Meeting in Madrid, Spain.

The study is titled A Phase 2 study safety and efficacy of anabasum (JBT-101) in systemic sclerosis.

Read the full article at markets.businessinsider.com

 

Need Help Finding a Physician?

Call us toll-free at:
+1.877.606.1555

Conditions & Treatments

adult child
Select A Body Part
Conditions: Adult head Conditions: Adult spine Conditions: Adult shoulder Conditions: Adult elbow Conditions: Adult hand Conditions: Adult hip Conditions: Adult knee Conditions: Adult ankle Conditions: Adult head Conditions: Adult full body Conditions: Child spine Conditions: Child elbow Conditions: Child hip Conditions: Child hand Conditions: Child knee Conditions: Child ankle Conditions: Child full body


Conditions A-Z
A B C D E F G H I
J K L M N O P Q R
S T U V W X Y Z
SEE ALL

Media Contacts

Tracy Hickenbottom
Monique Irons
Sherry Randolph

212.606.1197
mediarelations@hss.edu

Social Media Contacts

Andrew Worob
Otis Gamboa
socialmediacontact@hss.edu